ZNF232 is a nuclear zinc finger transcription factor located on chromosome 17 that likely regulates gene expression through RNA polymerase II-mediated mechanisms. Structurally, it contains a SCAN/LeR domain and five C(2)H(2)-type zinc fingers organized across three exons, encoding a 417 amino acid protein 1. The gene exhibits widespread expression across adult human tissues and undergoes tissue-specific post-transcriptional regulation via alternative splicing 1. Regarding disease relevance, ZNF232 has been associated with multiple pathological conditions. In a large-scale exome-wide association study of 30,312 lung cancer patients and 652,902 controls, ZNF232 was identified as a novel gene-level association signal for lung cancer predisposition 2. Additionally, ZNF232 variants were associated with hematological measurements and immune-related traits in Alzheimer's Disease and frontotemporal dementia genetic studies, suggesting potential roles in neuroinflammation and microglial function 3. In hepatocellular carcinoma, the ZNF232 antisense transcript (ZNF232-AS1) was identified as part of a disulfidptosis-related lncRNA prognostic signature 4. A chr17 breakpoint near ZNF232 was noted in Asperger syndrome patients, though gene expression appeared unaltered 5. ZNF232 also emerged as a core transcription factor in pluripotent stem cell differentiation states 6.